Polyrizon (PLRZ)
Develops NASARIX and intranasal hydrogel drug-delivery platforms.
Something off on this page? Send us feedback.
Develops drug-free and API-delivery intranasal products around mucoadhesive hydrogel platforms, led by NASARIX, an allergy barrier designed to separate airborne allergens from nasal mucosa. It has no approved products or revenue, relying on clinical, regulatory and partner-led execution.
Develops mucoadhesive hydrogel platforms for intranasal products. Its lead program, drug-free NASARIX, is designed to form a physical barrier between airborne allergens and nasal mucosa for seasonal allergic rhinitis. Capture & Contain is the core platform; a separate candidate targets viral exposure, while the earlier Trap & Target platform is intended to deliver active pharmaceutical ingredients in the nose.
Coordinates formulation, testing, regulatory work and clinical evidence through external partners across Israel, Europe and the United States. NASARIX has central master-protocol IRB approval and contracted U.S. clinical sites, although individual sites still require local activation before enrollment. No candidate is approved or sold, so operations depend on clinical execution, regulatory clearance and CROs, manufacturing partners, academic collaborators and clinical sites.
Company facts
Categories
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $12.3M · Total debt $0 · Total assets $21.4M · Shareholders' equity $21.0M
- Revenue
- $0
- Operating income
- −$3.8M
- Net income
- −$3.2M
No dividends on record.
| Institutions2 holders · as of Sep 30, 2025 | 0.18% | 2.1K ADS | |
| Otherremainder | 99.82% | 1.12M ADS |
1.12M ADS as of Aug 21, 2026 · institutions as of Sep 30, 2025 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
UBS Group AGInstitution | 0.18% | 12,267 ADS | 13Fas of Sep 30, 2025 |
Citigroup IncInstitution | 0.00% | 115 ADS | 13Fas of Sep 30, 2025 |
Oz Adler1Insiderdirector | — | — | Form 4filed Apr 1, 2026 ↗ |
Nir BenYosef1Insiderofficer: Chief Financial Officer | — | — | Form 4filed Mar 18, 2026 ↗ |
Liron Carmel1Insiderdirector | — | — | Form 4filed Apr 1, 2026 ↗ |
| See all 9 → | |||
- This position is filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 31, 2026 | Oz Adler | director | −3,292 | $12.05 |
| Mar 31, 2026 | Liron Carmel | director | −942 | $12.36 |
| Mar 31, 2026 | Tomer Izraeli | director, officer: Chief Executive Officer | −500 | $11.85 |
| Mar 30, 2026 | Tidhar Turgeman | director, officer: Chief Technology Officer | −2,917 | $10.90 |
| Mar 30, 2026 | Tomer Izraeli | director, officer: Chief Executive Officer | −3,900 | $10.90 |
- Haleon (ADR)
Flonase targets the same OTC nasal-allergy occasions.
- Kenvue
Rhinocort offers intranasal steroid relief for hay fever.
- Viatris
Dymista combines antihistamine and steroid nasal relief.
- Teva (ADR)
Generic Dymista-equivalent sprays target seasonal rhinitis.
- Perrigo
Store-brand nasal sprays compete on price and shelf space.
- Emergent BioSolutions
NARCAN and KLOXXADO lead commercial nasal naloxone delivery.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Polyrizon | $12.50 | −1.96% | $14.0M | — | — | — | — |
| Haleon (ADR) | $9.87 | −0.55% | $43.64B | 20.4 | 10.7 | 2.9 | +3.7% |
| Kenvue | $19.07 | −0.28% | $36.73B | 22.0 | 16.0 | 2.4 | +3.0% |
| Viatris | $16.92 | −1.00% | $19.90B | — | 6.7 | 1.4 | +4.9% |
| Teva (ADR) | $37.49 | +0.05% | $43.66B | 62.5 | 13.3 | 2.4 | −0.8% |
| Perrigo | $14.05 | −2.97% | $2.00B | — | 6.1 | 0.5 | −3.2% |
| Emergent BioSolutions | $6.42 | −0.70% | $333.3M | — | — | 0.4 | +66.3% |
| Median | 22.0 | 10.7 | 1.9 | +3.4% |